PIVOT PHARMACEUTICALS INC. (OTCMKTS:PVOTF) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement
On December 17, 2018, we entered into a Unanimous Shareholders’ Agreement with Cartagena Leaf Inc., a subsidiary of Mexico-based Licorera Del Sur, to create a joint venture corporation. The joint venture corporation will develop and commercialize cannabis-infused non-alcoholic beverages combining the expertise of Licorera del Sur with our patented Solumer™ and RTIC™ powderization technologies.
Item 9.01 Financial Statements and Exhibits
|
10.38 |
Unanimous Shareholders’ Agreement with Cartagena Leaf Inc. |
Pivot Pharmaceuticals Inc. Exhibit
EX-10.38 2 pvotf_ex1038.htm UNANIMOUS SHAREHOLDERS’ AGREEMENT pvotf_ex1038.htmEXHIBIT 10.38 UNANIMOUS SHAREHOLDERS’ AGREEMENT THIS AGREEMENT made as of the 17th day of December,…
To view the full exhibit click here
About PIVOT PHARMACEUTICALS INC. (OTCMKTS:PVOTF)
Pivot Pharmaceuticals Inc., formerly Neurokine Pharmaceuticals Inc., is a development-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic pharmaceutical products. The Company is in the business of developing and commercializing new uses for existing prescription drugs, as well as developing encapsulation technology in the treatment of neurodegenerative diseases. The Company’s research and development activities are focused on advancing drug candidates for the treatment of women’s cancers, including, but not limited to metastatic endometrial cancer and triple-negative breast cancer; leveraging drug delivery treatment options to allow targeted delivery of drugs to address women’s health needs in urological and/or gynecological indications, and opportunistically in-licensing later-stage drug candidates to augment its drug pipeline.